Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
The Oncologist|October 26, 2018
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine TumorsMarianne E Pavel, Alexandria T Phan, Edward M Wolin, et al.Endocrine|October 14, 2020
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension studyMartyn E Caplin, Marianne Pavel, Alexandria T Phan, et al.Clinical Nuclear Medicine|March 7, 2017
Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' AssessmentMohammadali Hamiditabar, Muzammil Ali, Joseph Roys, et al.The American Surgeon|November 5, 2009
Pancreatic neuroendocrine tumors: presentation, management, and outcomesNicholas N Nissen, Amanda S Kim, Run Yu, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 16, 2014
Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspectiveKen Herrmann, Johannes Czernin, Edward M Wolin, et al.Oncotargets and Therapy|July 20, 2017
Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumorsJames C Yao, Jennifer A Chan, Alain C Mita, et al.Pancreas|December 6, 2014
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trialCatherine Lombard-Bohas, James C Yao, Timothy Hobday, et al.Endocrine-Related Cancer|March 24, 2022
Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance)Matthew H Kulke, Fang-Shu Ou, Donna Niedzwiecki, et al.Journal of the Endocrine Society|June 7, 2022
The Mount Sinai Clinical Pathway for the Diagnosis and Management of Hypercortisolism due to Ectopic ACTH SyndromeEva L Alba, Emily A Japp, Gustavo Fernandez-Ranvier, et al.Oncotargets and Therapy|October 31, 2017
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4Roberto Buzzoni, Carlo Carnaghi, Jonathan Strosberg, et al.Pageof 5